Wynn Thomas A
Immunopathogenesis Section, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
J Clin Invest. 2007 Mar;117(3):524-9. doi: 10.1172/JCI31487.
Fibroproliferative diseases, including the pulmonary fibroses, systemic sclerosis, liver cirrhosis, cardiovascular disease, progressive kidney disease, and macular degeneration, are a leading cause of morbidity and mortality and can affect all tissues and organ systems. Fibrotic tissue remodeling can also influence cancer metastasis and accelerate chronic graft rejection in transplant recipients. Nevertheless, despite its enormous impact on human health, there are currently no approved treatments that directly target the mechanism(s) of fibrosis. The primary goals of this Review series on fibrotic diseases are to discuss some of the major fibroproliferative diseases and to identify the common and unique mechanisms of fibrogenesis that might be exploited in the development of effective antifibrotic therapies.
纤维增生性疾病,包括肺纤维化、系统性硬化症、肝硬化、心血管疾病、进行性肾病和黄斑变性,是发病和死亡的主要原因,可影响所有组织和器官系统。纤维化组织重塑还可影响癌症转移,并加速移植受者的慢性移植排斥反应。然而,尽管其对人类健康有巨大影响,但目前尚无直接针对纤维化机制的获批治疗方法。本纤维化疾病综述系列的主要目标是讨论一些主要的纤维增生性疾病,并确定在开发有效的抗纤维化疗法中可能会利用的纤维化形成的共同和独特机制。